| Drug Name |
Salmeterol xinafoate |
| Drug ID |
BADD_D01982 |
| Description |
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol].[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737]
Salmeterol was granted FDA approval on 4 February 1994.[L11542] |
| Indications and Usage |
For the treatment of asthma and chronic obstructive pulmonary disease (COPD). |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
R03AC12 |
| DrugBank ID |
DB00938
|
| KEGG ID |
D00687
|
| MeSH ID |
D000068299
|
| PubChem ID |
56801
|
| TTD Drug ID |
D0L5YV
|
| NDC Product Code |
14501-0045; 63190-0650; 52482-002; 50909-4102; 0173-0521; 58032-0143; 53104-7541; 64567-0007; 52221-109; 15308-1021; 55018-402 |
| Synonyms |
Salmeterol Xinafoate | Xinafoate, Salmeterol | Salmeterol | Serevent |
